Charis Bioscience

Charis Biosciences is a St. Louis-based biotechnology company focused on the development of therapies for rare and neglected diseases. Founded by Dr. Michael Kinch, the company specializes in a "re-innovation" strategy, which involves identifying and acquiring drug candidates that have been previously studied but not fully developed for specific orphan indications. Charis focuses primarily on central nervous system (CNS) and metabolic disorders, aiming to leverage existing safety and clinical data to accelerate the path to regulatory approval. By focusing on high-unmet-need areas like Niemann-Pick Disease Type C, the company seeks to provide novel treatment options for patient populations with few alternatives.